Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 May;75(9):4165-75.
doi: 10.1128/JVI.75.9.4165-4175.2001.

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

N L Letvin  1 , S Robinson, D Rohne, M K Axthelm, J W Fanton, M Bilska, T J Palker, H X Liao, B F Haynes, D C Montefiori
Affiliations

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

N L Letvin et al. J Virol. 2001 May.

Abstract

Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Location and sequence of the C4/89.6-V3 and C4/89.6P-V3 peptides. Peptides 39 amino acids in length contained sequences from the crown and N-terminal portion of the V3 loop synthesized C-terminal to a 16-amino-acid stretch of the C4 helper determinant of gp120. The 89.6 and 89.6P peptides differed by a single arginine (R)-to-glutamic acid (E) substitution in V3 as shown.
FIG. 2
FIG. 2
Neutralizing antibody response in peptide-immunized animals before and after challenge with SHIV-89.6. Animals were inoculated with either C4/scbl-V3 (A) or C4/89.6-V3 (B) at weeks 0, 4, 12, 24, 89, 95, 101, and 111 and were challenged with SHIV-89.6 at week 113. Neutralizing antibodies to SHIV-89.6 were measured in MT-2 cells at multiple times before and after challenge. Peptide inoculations were made at the times indicated (∧). Arrow, day of challenge. The lowest serum dilution tested was 1:20 (negative results were given a value of 20 for presentation).
FIG. 3
FIG. 3
Neutralizing antibody response in peptide-immunized animals before and after challenge with either SHIV-89.6P or SHIV-89.6. Animals were inoculated with either C4/scbl-V3 or C4/89.6P-V3 at weeks 0, 6, 12, 18, 24, and 31 and were challenged with either SHIV-89.6P or SHIV-89.6 at week 33. Neutralizing antibodies to SHIV-89.6 (A) and SHIV-89.6P (B) were measured in MT-2 cells at multiple times throughout the immunization schedule and postchallenge. Peptide inoculations were made at the times indicated (∧). Arrow, day of challenge. The lowest serum dilution tested was 1:20 for SHIV-89.6 and 1:5 for SHIV-89.6P (negative results were given values of 20 and 5, respectively, for presentation).
FIG. 4
FIG. 4
Neutralizing antibody specificity generated by C4/89.6-V3 peptide immunization. Serum samples were obtained 2 weeks after final boosting with the C4/89.6-V3 peptide. Each serum sample was incubated for 1 h at 37°C with either no peptide (solid circles), C4/scbl-V3 peptide (open circles), or C4/89.6-V3 peptide (solid inverted triangles) and then assessed for neutralizing activity against SHIV-89.6 in MT-2 cells.
FIG. 5
FIG. 5
Sequential plasma viral load measurements in rhesus monkeys immunized with a control peptide (C4/scbl-V3), an experimental homologous peptide (C4/89.6-V3), or a control heterologous peptide (C4/89.6P-V3) after intravenous challenge with SHIV-89.6.
FIG. 6
FIG. 6
Sequential plasma viral load measurements in rhesus monkeys immunized with a control peptide (C4/scbl-V3) or experimental homologous peptide (C4/89.6P) after intravenous challenge with SHIV-89.6P.
FIG. 7
FIG. 7
Sequential peripheral blood CD4+ lymphocyte counts in rhesus monkeys immunized with a control peptide (C4/scbl-V3) or experimental homologous peptide (C4/89.6P) after intravenous challenge with SHIV-89.6P.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Eastbrook P J, Simmonds P, Weber J. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 1998;79:77–82. - PubMed
    1. Bou-Habib D C, Roderiquez G, Oravecz T, Berman P W, Lusso P, Norcross M A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol. 1994;68:6006–6013. - PMC - PubMed
    1. Bures, R., A. Gaitan, T. Zhu, C. Graziosi, K. McGrath, J. Tartaglia, P. Caudrelier, R. E. L. Habib, M. Klein, A. Lazzarin, D. Stablein, M. Deers, L. Corey, M. L. Greenberg, D. H. Schwartz, and D. C. Montefiori. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses, in press. - PubMed
    1. Burton D R. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA. 1997;94:10018–10023. - PMC - PubMed
    1. Cheingsong-Popov R, Osmanov S, Pau C-P, Schochetman G, Barin F, Holmes H, Francis G, Ruppach H, Dietrich U, Lister S, Weber J. Serotyping of HIV-1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. AIDS Res Hum Retroviruses. 1998;14:311–318. - PubMed

Publication types